Ophthalmology Science (Mar 2024)

Trends in Research Payments for Diabetic Macular Edema from 2015 to 2021

  • April M. Lee, BS,
  • Timothy T. Xu, MD,
  • Matthew R. Starr, MD

Journal volume & issue
Vol. 4, no. 2
p. 100379

Abstract

Read online

Purpose: To evaluate characteristics of research payments for diabetic macular edema (DME) studies and correlations to current management trends. Design: Retrospective cross-sectional study. Subjects: Research payments for DME. Methods: Studies with keywords of “diabetic macular edema” or “DME” in the title were extracted from the Centers of Medicare & Medicaid Services Open Payments database from 2015 to 2021. Recipients, payors, and payment amounts were identified. Industry funding was compared with public research funding by the National Eye Institute (NEI). Main Outcome Measures: Trends and total value of industry and public fundings for DME from 2015 to 2021. Results: From 2015 to 2021, 451 beneficiaries received 6062 industry payments for a total of $120 148 997.41 for DME-related research. The total value of industry funding increased from $8 225 859.08 in 2015 to $50 092 778.45 in 2021. Of the 6062 industry payments, 5367 (88.5%) were reported by male recipients compared with 695 (11.5%) female beneficiaries. Payments to female recipients increased from 60 (7.1%) in 2015 to 335 (13.7%) in 2021. In comparison, public funding for DME-related research from the NEI was comprised of $18 863 266.00 to 17 principal investigators from 2015 to 2021. The total value of public funding increased from $973 590.00 in 2015 to $3 354 376.00 in 2021. Of 59 public research payments, 46 (78.0%) were reported by male recipients and 13 (22.0%) by female recipients. Payments to female recipients increased from 1 (25.0%) in 2015 to 3 (30.0%) in 2021. The most highly invested product by industry were anti-VEGF agents, accounting for $89 955 595.20 (74.9%) of total payment value. Conclusions: There was an increase in both industry and public-sponsored funding for DME-related research from 2015 to 2021. There seemed to be a possible discrepancy in both industry and public funding based on sex for DME studies during the study period. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Keywords